Insulin-like growth factor 1

Synthesis and circulation

The polypeptide hormone IGF-1 is synthesized primarily in the liver upon stimulation by growth hormone (GH). It is a key mediator of anabolic activities in numerous tissues and cells, such as growth hormone-stimulated growth, metabolism and protein translation. Due to its participation in the GH-IGF-1 axis it contributes among other things to the maintenance of muscle strength, muscle mass, development of the skeleton and is a key factor in brain, eye and lung development during fetal development.

Studies have shown the importance of the GH/IGF-1 axis in directing development and growth, where mice with an IGF-1 deficiency had a reduced body- and tissue mass. Mice with an excessive expression of IGF-1 had an increased mass.

The levels of IGF-1 in the body vary throughout life, depending on age, where peaks of the hormone is generally observed during puberty and the postnatal period. After puberty, when entering the third decade of life, there is a rapid decrease in IGF-1 levels due to the actions of GH. Between the third and eighth decade of life, the IGF-1 levels decrease gradually, but unrelated to functional decline. However, protein intake is proven to increase IGF-1 levels.[[Image:IGF-1.GIF|thumb|right|3-d model of IGF-1]]

Mechanism of action

IGF-1 is a primary mediator of the effects of growth hormone (GH). Growth hormone is made in the anterior pituitary gland, released into the bloodstream, and then stimulates the liver to produce IGF-1. IGF-1 then stimulates systemic body growth, and has growth-promoting effects on almost every cell in the body, especially skeletal muscle, cartilage, bone, liver, kidney, nerve, skin, hematopoietic, and lung cells. In addition to its insulin-like effects (insulin being the main anabolic hormone in the body), IGF-1 can also regulate cellular DNA synthesis.

IGF-1 binds to at least two cell surface receptor tyrosine kinases: the IGF-1 receptor (IGF1R), and the insulin receptor. Its primary action is mediated by binding to its specific receptor, IGF1R, which is present on the surface of several cell types in a multitude of tissues. Binding to the IGF1R initiates intracellular signaling. IGF-1 is one of the most potent natural activators of the Akt signaling pathway, a stimulator of cell growth and proliferation, and a potent inhibitor of programmed cell death. The IGF-1 receptor and insulin receptor are two closely related members of a transmembrane tetrameric tyrosine kinase receptor family. They control vital brain functions, such as survival, growth, energy metabolism, longevity, neuroprotection and neuroregeneration.

Metabolic effects

As a major growth factor, IGF-1 is responsible for stimulating growth of all cell types, and causing significant metabolic effects. One important metabolic effect of IGF-1 is signaling cells that sufficient nutrients are available for them to undergo hypertrophy and cell division. Its effects also include inhibiting cell apoptosis and increasing the production of cellular proteins. IGF-1 receptors are ubiquitous, which allows for metabolic changes caused by IGF-1 to occur in all cell types. IGF-1's metabolic effects are far-reaching and can coordinate protein, carbohydrate, and fat metabolism in a variety of different cell types. The regulation of IGF-1's metabolic effects on target tissues is also coordinated with other hormones such as growth hormone and insulin.

The IGF system

IGF-1 is part of the insulin-like growth factor (IGF) system. This system consists of three ligands (insulin, IGF-1 and IGF-2), two tyrosine kinase receptors (insulin receptor and IGF-1R receptor) and six ligand binding proteins (IGFBP 1–6). Together they play an essential role in proliferation, survival, regulation of cell growth and affect almost every organ system in the body.

Similarly to IGF-1, IGF-2 is mainly produced in the liver and after it is released into circulation, it stimulates growth and cell proliferation. IGF-2 is thought to be a fetal growth factor, as it is essential for a normal embryonic development and is highly expressed in embryonic and neonatal tissues.

Variants

A splice variant of IGF-1 sharing an identical mature region, but with a different E domain is known as mechano growth factor (MGF).

Related disorders

Laron syndrome

Acromegaly

Acromegaly is a syndrome caused by the anterior pituitary gland producing excess growth hormone (GH). A number of disorders may increase the pituitary's GH output, although most commonly it involves a tumor called pituitary adenoma, derived from a distinct type of cell (somatotrophs). It leads to anatomical changes and metabolic dysfunction caused by elevated GH and IGF-1 levels.

High level of IGF-1 in acromegaly is related to an increased risk of some cancers, particularly colon cancer and thyroid cancer.

Use as a diagnostic test

Growth hormone deficiency

IGF-1 levels can be analyzed and used by physicians as a screening test for growth hormone deficiency (GHD), acromegaly and gigantism. However, IGF-1 has been shown to be a bad diagnostic screening test for growth hormone deficiency.

The ratio of IGF-1 and insulin-like growth factor-binding protein 3 has been shown to be a useful diagnostic test for GHD.

Liver fibrosis

Low serum IGF-1 levels have been suggested as a biomarker for predicting fibrosis, but not steatosis, in people with metabolic dysfunction–associated steatotic liver disease.

Causes of elevated IGF-1 levels

• Medical conditions:
  • acromegaly (especially when GH is also high)
  • delayed puberty
  • pregnancy
  • hyperthyroidism
  • some rare tumors, such as carcinoids, secreting IGF-1
• Diet:
  • High-protein diet
  • consumption of dairy products (except for cheese)
  • consumption of fish
• IGF-1 assay problems Calorie restriction has been found to have no effect on IGF-1 levels.

Causes of reduced IGF-1 levels

• Metabolic dysfunction–associated steatotic liver disease, especially at advanced stages of steatohepatitis and fibrosis
• Oral estrogens suppress growth hormone-induced IGF-1 production in the liver by antagonism of growth hormone receptors.

Health effects

Mortality

Both high and low levels of IGF‐1 increase mortality risk, with the mid‐range (120–160 ng/ml) being associated with the lowest mortality.

Dairy consumption

It has been suggested that consumption of IGF-1 in dairy products could increase cancer risk, particularly prostate cancer. However, significant levels of intact IGF-1 from oral consumption are not absorbed as they are digested by gastric enzymes. IGF-1 present in food is not expected to be active within the body in the way that IGF-1 is produced by the body itself.

The Food and Drug Administration has stated that IGF-I concentrations in milk are not significant when evaluated against concentrations of IGF-I endogenously produced in humans.

A 2018 review by the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC) concluded that there is "insufficient evidence to draw any firm conclusions as to whether exposure to dietary IGF-1 is associated with an increased incidence of cancer in consumers". Certain dairy processes such as fermentation are known to significantly decrease IGF-1 concentrations. The British Dietetic Association has described the idea that milk promotes hormone related cancerous tumor growth as a myth, stating "no link between dairy containing diets and risk of cancer or promoting cancer growth as a result of hormones".

Cardiovascular disease

Increased IGF-1 levels are associated with a 16% lower risk of cardiovascular disease and a 28% reduction of cardiovascular events.

Diabetes

Low IGF-1 levels are shown to increase the risk of developing type 2 diabetes and insulin resistance. On the other hand, a high IGF-1 bioavailability in people with diabetes may delay or prevent diabetes-associated complications, as it improves impaired small blood vessel function.

IGF-1 has been characterized as an insulin sensitizer.

Low serum IGF‐1 levels can be considered an indicator of liver fibrosis in type 2 diabetes mellitus patients.

References

References

1. (2013). "Anabolic effects of IGF-1 signaling on the skeleton". Frontiers in Endocrinology.
2. (June 1957). "A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro". The Journal of Laboratory and Clinical Medicine.
3. (April 1978). "NSILA-carrier protein abolishes the action of nonsuppressible insulin-like activity (NSILA-S) on perfused rat heart". Diabetologia.
4. (1985). "The human gene encoding insulin-like growth factor I is located on chromosome 12". Human Genetics.
5. (1983). "Sequence of cDNA encoding human insulin-like growth factor I precursor". Nature.
6. (April 1978). "The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin". The Journal of Biological Chemistry.
7. (February 2022). "Big dog, little dog: mutation explains range of canine sizes". Nature.
8. (2017). "IGF-1 Induces GHRH Neuronal Axon Elongation during Early Postnatal Life in Mice". PLOS ONE.
9. (December 1988). "Serum insulin-like growth factor I (somatomedin-C) level in normal subjects from infancy to adulthood, pituitary dwarfs and normal variant short children". Endocrinologia Japonica.
10. (September 1994). "Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin". Clinical Endocrinology.
11. (2008). "Mecasermin". BioDrugs.
12. (January 2023). "Cyclic Glycine-Proline (cGP) Normalises Insulin-Like Growth Factor-1 (IGF-1) Function: Clinical Significance in the Ageing Brain and in Age-Related Neurological Conditions". Molecules.
13. (September 2020). "IGF-1 and cardiometabolic diseases: a Mendelian randomisation study". Diabetologia.
14. (2020-04-01). "The influence of zinc supplementation on IGF-1 levels in humans: A systematic review and meta-analysis". Journal of King Saud University - Science.
15. (September 2019). "Seasonal expressions of growth hormone receptor, insulin-like growth factor 1 and insulin-like growth factor 1 receptor in the scented glands of the muskrats (Ondatra zibethicus)". General and Comparative Endocrinology.
16. (March 2014). "Low protein intake is associated with a major reduction in IGF-1, cancer, and overall mortality in the 65 and younger but not older population". Cell Metabolism.
17. (2011). "Biochemistry". Wiley.
18. (September 2002). "Circulating levels of IGF-1 directly regulate bone growth and density". The Journal of Clinical Investigation.
19. (October 1999). "Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis". Molecular and Cellular Biology.
20. (June 1999). "c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release". Genes & Development.
21. (February 2010). "Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling". Neurobiology of Aging.
22. (June 2012). "Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes". Endocrinology and Metabolism Clinics of North America.
23. (November 2015). "Role of IGF-I signaling in muscle bone interactions". Bone.
24. (January 2004). "The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity". The Journal of Clinical Investigation.
25. (September 2021). "Insulin-like Growth Factor 1 Signaling in Mammalian Hearing". Genes.
26. (March 2011). "The IGF system". Acta Diabetologica.
27. (2006). "Encyclopedia of Respiratory Medicine".
28. (February 2008). "Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction". Heart, Lung & Circulation.
29. "Acromegaly - NIDDK".
30. (April 2014). "Expert consensus document: A consensus on the medical treatment of acromegaly". Nature Reviews. Endocrinology.
31. (August 2018). "Acromegaly: a challenging condition to diagnose". International Journal of General Medicine.
32. (April 2015). "Diagnostic value of serum IGF-1 and IGFBP-3 in growth hormone deficiency: a systematic review with meta-analysis". European Journal of Pediatrics.
33. (December 2014). "Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation". The New England Journal of Medicine.
34. (August 2021). "Insulin-like growth factor-1 level is a poor diagnostic indicator of growth hormone deficiency". Scientific Reports.
35. (February 2023). "Diagnostic Value of IGF-1 in Growth Hormone-Deficient Children: Is a Second Growth Hormone Stimulation Test Necessary?". Journal of the Endocrine Society.
36. (March 2023). "Serum IGF-1 to IGFBP-3 Molar Ratio: A Promising Diagnostic Tool for Growth Hormone Deficiency in Children". The Journal of Clinical Endocrinology and Metabolism.
37. (March 2023). "IGF-1/IGFBP-3 Serum Ratio as a Robust Measure to Determine GH Deficiency and Guide Human Recombinant GH Therapy". The Journal of Clinical Endocrinology and Metabolism.
38. (2021-06-23). "Adiponectin, Leptin, and IGF-1 Are Useful Diagnostic and Stratification Biomarkers of NAFLD". Frontiers in Medicine.
39. (2010). "Spuriously Elevated Serum IGF-1 in Adult Individuals with Delayed Puberty: A Diagnostic Pitfall". International Journal of Endocrinology.
40. (August 2009). "Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?". Clinical Endocrinology.
41. (October 2009). "Bronchial carcinoid secreting insulin-like growth factor-1 with acromegalic features". The Annals of Thoracic Surgery.
42. (June 2020). "Effect of calorie restriction or protein intake on circulating levels of insulin like growth factor I in humans: A systematic review and meta-analysis". Clinical Nutrition.
43. (February 2023). "Associations between food group intakes and circulating insulin-like growth factor-I in the UK Biobank: a cross-sectional analysis". European Journal of Nutrition.
44. (July 2023). "Growth hormone and nonalcoholic fatty liver disease". Immunometabolism.
45. (February 2017). "A summary of the influence of exogenous estrogen administration across the lifespan on the GH/IGF-1 axis and implications for bone health". Growth Hormone & IGF Research.
46. (February 2022). "Association between IGF-1 levels ranges and all-cause mortality: A meta-analysis". Aging Cell.
47. (June 2017). "Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis". Cancer Causes & Control.
48. "Statement on possible carcinogenic hazard to consumers from insulin-like growth factor-1 (IGF-1) in the diet". assets.publishing.service.gov.uk.
49. (August 1990). "Bovine Growth Hormone: Human Food Safety Evaluation". Science.
50. (2000). "FDA rejects petition to ban rBST".
51. (August 2017). "Analysis of the IGF-system in milk from farm animals - Occurrence, regulation, and biomarker potential". Growth Hormone & IGF Research.
52. (2024). "Cancer Diets: Myths and More".
53. (December 2022). "Association between insulin-like growth factor-1 and cardiovascular events: a systematic review and dose-response meta-analysis of cohort studies". Journal of Endocrinological Investigation.
54. (2021-05-01). "Insulin-like Growth Factor and its Therapeutic Potential for Diabetes Complications - Mechanisms and Metabolic Links: A Review". The Review of Diabetic Studies.
55. (January 2007). "Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults". Diabetes, Obesity & Metabolism.
56. (July 2019). "Insulin-like growth factor-1 is inversely associated with liver fibrotic markers in patients with type 2 diabetes mellitus". Journal of Diabetes Investigation.